Dr. Eun-mi Yu, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Drexel University College of Medicine (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 224
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Drexel University College of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
VA license 0101269851 -
Hematology (Internal Medicine) Physician
VA license 0101269851 -
Hematology & Oncology Physician
NC license 2015-00321 -
Internal Medicine Physician
VA license 0101269851
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Inova Fairfax Hospital Falls Church, VA
- Inova Alexandria Hospital Alexandria, VA
- Inova Fair Oaks Hospital Fairfax, VA
- Inova Loudoun Hospital Leesburg, VA
- Inova Mount Vernon Hospital Alexandria, VA
Medical groups
- Inova Health Care Services (1,817 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 224
- Services billed
- 541
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 453 | 139 |
| Established patient office or other outpatient visit, 30-39 minutes | 123 | 80 |
| New patient office or other outpatient visit, 60-74 minutes | 61 | 61 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 13 |
| New patient office or other outpatient visit, 45-59 minutes | 13 | 13 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Orgovyx (relugolix) | 179 |
| Prednisone Other prescribers in Fairfax, VA | 81 |
| Nubeqa (darolutamide) | 71 |
| Xtandi (enzalutamide) | 52 |
| Abiraterone Acetate | 52 |
| Inlyta (axitinib) | 30 |
| Hydrocortisone Other prescribers in Fairfax, VA | 28 |
| Gabapentin Other prescribers in Fairfax, VA | 27 |
| Bicalutamide | 26 |
| Eliquis (apixaban) Other prescribers in Fairfax, VA | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $112,847 in research payments for these studies, mostly to the institutions running them.
- A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Ca…
AstraZeneca Pharmaceuticals LP - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Aveo Pharmaceuticals, Inc. · Completed · NCT04987203
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.